Skip to content
Catalyst

phylloquinoneWhat was measured

Measured, with no finding

918 endpoints

Show what was measuredHide what was measured
  • baseline %carbOC correlation with BMD of femoral neck

    increases

    Baseline %carbOC of the entire study population was positively correlated with BMD of the lumbar spine and femoral neck

    PMID 10951511 · one of two readings recorded this

  • baseline %carbOC correlation with BMD of lumbar spine

    increases

    Baseline %carbOC of the entire study population was positively correlated with BMD of the lumbar spine and femoral neck

    PMID 10951511 · one of two readings recorded this

  • maximum increase in serum 25-hydroxyvitamin D [25(OH)D]

    increases

    One year of supplementation with vitamin D(3) showed maximum increases in 25(OH)D of 33+/-29% (95% CI, 24.8-41.8%) and 68+/-58% (95% CI, 50.1-84.6%) in women with normal and low BMD, respectively

    PMID 10951511 · one of two readings recorded this

  • maximum increase in serum 25-hydroxyvitamin D [25(OH)D]

    increases

    One year of supplementation with vitamin D(3) showed maximum increases in 25(OH)D of 33+/-29% (95% CI, 24.8-41.8%) and 68+/-58% (95% CI, 50.1-84.6%) in women with normal and low BMD, respectively

    PMID 10951511 · one of two readings recorded this

  • percentage carboxylated osteocalcin (%carbOC)

    unclear

    ((mean+/-s.d.) 68+/-11% (95% CI, 64. 5-71.2%) vs 72+/-6% (95% CI, 70.1-72.9%)

    PMID 10951511 · one of two readings recorded this

  • percentage carboxylated osteocalcin (%carbOC)

    unclear

    ((mean+/-s.d.) 68+/-11% (95% CI, 64. 5-71.2%) vs 72+/-6% (95% CI, 70.1-72.9%)

    PMID 10951511 · one of two readings recorded this

  • winter decline in maximum 25(OH)D levels

    decreases

    During winter, however, a 29% decline in maximum 25(OH)D levels was not prevented in women with low BMD

    PMID 10951511 · one of two readings recorded this

  • baseline serum phylloquinone concentration

    unclear

    At baseline, the mean serum phylloquinone concentration was lower in the young than in the old group; there was no effect of sex

    PMID 11101481 · one of two readings recorded this

  • baseline %ucOC

    unclear, p = 0.0001

    Concomitantly, baseline %ucOC was highest in the young and lowest in the old men (P: < 0.0001) but did not differ significantly by age in women

    PMID 11101481 · one of two readings recorded this

  • baseline %ucOC

    no effect

    Concomitantly, baseline %ucOC was highest in the young and lowest in the old men (P: < 0.0001) but did not differ significantly by age in women

    PMID 11101481 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%ucOC) in serum, before and after 1000 microg/d phylloquinone or placebo for 2 weeks

    decreases

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Among all supplemented groups, mean %ucOC decreased from 7.6% to 3. 4% without significant differences by age or sex; 102 of 112 subjects had a >1% decrease.

    PMID 11101481 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%ucOC)

    decreases

    Among all supplemented groups, mean %ucOC decreased from 7.6% to 3. 4% without significant differences by age or sex

    PMID 11101481 · one of two readings recorded this

  • serum bone-specific alkaline phosphatase (BSAP)

    no effect

    Phylloquinone supplementation reduced serum osteocalcin but did not alter NTx or BSAP concentration

    PMID 11101481 · one of two readings recorded this

  • serum N-telopeptides of type I collagen (NTx)

    no effect

    Phylloquinone supplementation reduced serum osteocalcin but did not alter NTx or BSAP concentration

    PMID 11101481 · one of two readings recorded this

  • serum phylloquinone concentration

    increases, p = 0.0001

    After supplementation, serum phylloquinone concentration increased approximately 10-fold (P: < 0.0001) at week 1 (from 0.93 +/- 0.08 to 8.86 +/- 0.70 nmol/L, x+/- SEM)

    PMID 11101481 · one of two readings recorded this

  • subjects with a >1% decrease in %ucOC

    decreases, n = 112

    102 of 112 subjects had a >1% decrease

    PMID 11101481 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%ucOC) in serum across phylloquinone doses of 250 to 2000 microg/d versus placebo

    decreases, %ucOC decreased dose-dependently; 250 microg/d differed from placebo; 1000 differed from 500 microg/d

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Phylloquinone supplementation decreased %ucOC dose-dependently; %ucOC was significantly different between the 250- micro g and the placebo groups and between the 1000- and 500- micro g groups but not between the 250-, 375-, and 500- micro g groups.

    PMID 12399278 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%ucOC)

    decreases

    %ucOC was significantly different between the 250- micro g and the placebo groups and between the 1000- and 500- micro g groups but not between the 250-, 375-, and 500- micro g groups

    PMID 12399278 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%ucOC)

    decreases, p = 0.0001

    In substudy A, %ucOC decreased with phylloquinone supplementation (P < 0.0001); a greater reduction was observed with 1000 and 2000 micro g than with 500 micro g (P < 0.05)

    PMID 12399278 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%ucOC)

    decreases, p = 0.05

    In substudy A, %ucOC decreased with phylloquinone supplementation (P < 0.0001); a greater reduction was observed with 1000 and 2000 micro g than with 500 micro g (P < 0.05)

    PMID 12399278 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%ucOC)

    decreases

    %ucOC was significantly different between the 250- micro g and the placebo groups and between the 1000- and 500- micro g groups but not between the 250-, 375-, and 500- micro g groups

    PMID 12399278 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%ucOC)

    decreases, p = 0.0001

    In substudy B, %ucOC decreased in all supplemented groups by week 1 (P for the trend < 0.0001), which was sustained through week 2

    PMID 12399278 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%ucOC)

    no effect

    %ucOC was significantly different between the 250- micro g and the placebo groups and between the 1000- and 500- micro g groups but not between the 250-, 375-, and 500- micro g groups

    PMID 12399278 · one of two readings recorded this

  • Elevated serum PIVKA-II at admission

    n = 18

    At admission, 18 infants (41%) had elevated levels of serum PIVKA-II and eight (18%) had low K(1) concentrations, indicative of subclinical vitamin K deficiency

    PMID 12598499 · one of two readings recorded this

  • Infants achieving incremental rise in serum K1 > 10 ng/ml after oral dose

    n = 24

    The severity of malabsorption was such that only 4/24 (17%) achieved an incremental rise in serum K(1) > 10 ng/ml

    PMID 12598499 · one of two readings recorded this

  • Median serum vitamin K1 24 hours after oral dose, cholestatic infants

    In the latter group, the low median value (0.95 ng/ml) and wide range (< 0.15-111 ng/ml) of serum K(1) compared unfavourably with the much higher levels (median 77, range 11-263 ng/ml) observed in healthy infants given the same oral dose

    PMID 12598499 · one of two readings recorded this

  • Median serum vitamin K1 24 hours after oral dose, healthy newborns

    n = 14

    In the latter group, the low median value (0.95 ng/ml) and wide range (< 0.15-111 ng/ml) of serum K(1) compared unfavourably with the much higher levels (median 77, range 11-263 ng/ml) observed in healthy infants given the same oral dose

    PMID 12598499 · one of two readings recorded this

  • Median serum vitamin K1 at baseline

    no effect

    Median serum K(1) concentrations were similar in the oral and intravenous groups at baseline (0.92 v 1.15 ng/ml), rising to 139 ng/ml six hours after intravenous K(1) but to only 1.4 ng/ml after oral administration

    PMID 12598499 · one of two readings recorded this

  • Median serum vitamin K1 six hours after dose

    increases

    Median serum K(1) concentrations were similar in the oral and intravenous groups at baseline (0.92 v 1.15 ng/ml), rising to 139 ng/ml six hours after intravenous K(1) but to only 1.4 ng/ml after oral administration

    PMID 12598499 · one of two readings recorded this

  • Median serum vitamin K1 six hours after dose

    increases

    Median serum K(1) concentrations were similar in the oral and intravenous groups at baseline (0.92 v 1.15 ng/ml), rising to 139 ng/ml six hours after intravenous K(1) but to only 1.4 ng/ml after oral administration

    PMID 12598499 · one of two readings recorded this

  • Blood coagulability, factor VII and X activities, PIVKA-II concentrations

    no effect

    Although vitamin K1 concentrations were statistically significantly higher in the intramuscular group, blood coagulability, activities of factors VII and X and PIVKA-II concentrations did not reveal any difference between the two groups

    PMID 1444522 · one of two readings recorded this

  • Infants with detectable PIVKA-II

    increases

    At 3 months vitamin K1 concentrations were back at unsupplemented values and PIVKA-II was detectable in 11.5% of infants

    PMID 1444522 · one of two readings recorded this

  • PIVKA-II detectable

    decreases

    At 2 weeks of age vitamin K1 concentrations were raised compared with reported unsupplemented concentrations and no PIVKA-II was detectable

    PMID 1444522 · one of two readings recorded this

  • Plasma vitamin K1 concentration

    increases

    Although vitamin K1 concentrations were statistically significantly higher in the intramuscular group, blood coagulability, activities of factors VII and X and PIVKA-II concentrations did not reveal any difference between the two groups

    PMID 1444522 · one of two readings recorded this

  • common carotid artery intima-media thickness, distensibility coefficient, compliance coefficient, pulse pressure and Young's modulus over three years

    no effect, no significant differences in the change of IMT between the three groups

    Not recorded as a finding: the intervention held more than the compound

    No significant differences were observed in the change of IMT between the three groups.

    PMID 14961167 · one of two readings recorded this

  • compliance coefficient (CC) decrease

    decreases, p = 0.05

    Comparing the MDK- and placebo-group, there were significant differences in decrease of DC (8.8%; p<0.05), CC (8.6%; p<0.05), and in increase of PP (6.3%; p<0.05) and E (13.2%, p<0.01)

    PMID 14961167 · one of two readings recorded this

  • distensibility coefficient (DC) decrease

    decreases, p = 0.05

    Comparing the MDK- and placebo-group, there were significant differences in decrease of DC (8.8%; p<0.05), CC (8.6%; p<0.05), and in increase of PP (6.3%; p<0.05) and E (13.2%, p<0.01)

    PMID 14961167 · one of two readings recorded this

  • elastic properties (DC, CC, PP, E)

    no effect

    There were no significant differences between the MD-group and placebo

    PMID 14961167 · one of two readings recorded this

  • intima-media thickness (IMT) change

    no effect

    No significant differences were observed in the change of IMT between the three groups

    PMID 14961167 · one of two readings recorded this

  • pulse pressure (PP) increase

    increases, p = 0.05

    Comparing the MDK- and placebo-group, there were significant differences in decrease of DC (8.8%; p<0.05), CC (8.6%; p<0.05), and in increase of PP (6.3%; p<0.05) and E (13.2%, p<0.01)

    PMID 14961167 · one of two readings recorded this

  • Young's Modulus (E) increase

    increases, p = 0.01

    Comparing the MDK- and placebo-group, there were significant differences in decrease of DC (8.8%; p<0.05), CC (8.6%; p<0.05), and in increase of PP (6.3%; p<0.05) and E (13.2%, p<0.01)

    PMID 14961167 · one of two readings recorded this

  • BMC of lumbar spine, lean tissue mass and fat mass by DXA; carboxylated and undercarboxylated osteocalcin

    increases, lumbar spine BMC P = 0.001, lean tissue mass P = 0.016, fat mass P = 0.014, treatment vs placebo

    Not recorded as a finding: the intervention held more than the compound

    Furthermore, there was a statistically significant increase in BMC of lumbar spine (P = 0.001), lean tissue mass (LTM: P = 0.016) and fat mass (FM: P = 0.014) in the treatment group when compared to the placebo group.

    PMID 16782422 · one of two readings recorded this

  • bone mineral content (BMC) of lumbar spine

    increases, p = 0.001

    a statistically significant increase in BMC of lumbar spine (P = 0.001)

    PMID 16782422 · one of two readings recorded this

  • bone mineral content (BMC) of lumbar spine

    increases, p = 0.015

    The significant increase in BMC of lumbar spine in the treatment group was present only in the prepubertal children (P = 0.015)

    PMID 16782422 · one of two readings recorded this

  • bone mineral content (BMC) of lumbar spine

    no effect

    The significant increase in BMC of lumbar spine in the treatment group was present only in the prepubertal children (P = 0.015)

    PMID 16782422 · one of two readings recorded this

  • carboxylated osteocalcin (cOC) concentration

    increases, p = 0.001

    carboxylated osteocalcin (cOC) concentration significantly increased (P < 0.001)

    PMID 16782422 · one of two readings recorded this

  • carboxylated osteocalcin (cOC) concentration

    increases, p = 0.001

    in prepubertal (P < 0.001 and P = 0.006 respectively) and pubertal children (P = 0.004 and P = 0.042 respectively)

    PMID 16782422 · one of two readings recorded this

  • carboxylated osteocalcin (cOC) concentration

    increases, p = 0.004

    in prepubertal (P < 0.001 and P = 0.006 respectively) and pubertal children (P = 0.004 and P = 0.042 respectively)

    PMID 16782422 · one of two readings recorded this

  • fat mass (FM)

    increases, p = 0.014

    fat mass (FM: P = 0.014)

    PMID 16782422 · one of two readings recorded this

  • lean tissue mass and fat mass by DXA; lumbar spine BMC; carboxylated and undercarboxylated osteocalcin

    increases

    Not recorded as a finding: the intervention held more than the compound

    Furthermore, there was a statistically significant increase in BMC of lumbar spine (P = 0.001), lean tissue mass (LTM: P = 0.016) and fat mass (FM: P = 0.014) in the treatment group when compared to the placebo group.

    PMID 16782422 · one of two readings recorded this

  • lean tissue mass (LTM)

    increases, p = 0.016

    lean tissue mass (LTM: P = 0.016)

    PMID 16782422 · one of two readings recorded this

  • undercarboxylated osteocalcin (ucOC) concentration

    decreases, p = 0.001

    undercarboxylated osteocalcin (ucOC) concentration significantly decreased (P = 0.001)

    PMID 16782422 · one of two readings recorded this

  • undercarboxylated osteocalcin (ucOC) concentration

    decreases, p = 0.006

    in prepubertal (P < 0.001 and P = 0.006 respectively) and pubertal children (P = 0.004 and P = 0.042 respectively)

    PMID 16782422 · one of two readings recorded this

  • undercarboxylated osteocalcin (ucOC) concentration

    decreases, p = 0.042

    in prepubertal (P < 0.001 and P = 0.006 respectively) and pubertal children (P = 0.004 and P = 0.042 respectively)

    PMID 16782422 · one of two readings recorded this

  • cross-linked C-telopeptide of type I collagen

    decreases

    cross-linked C-telopeptide of type I collagen >30%, total osteocalcin and type I N-terminal procollagen peptide >15%

    PMID 17030114 · one of two readings recorded this

  • serum phylloquinone

    increases, p = 0.05

    In vitamin K-supplemented women, mean serum phylloquinone concentrations increased from 0.27 to 0.76 microg/L (P < 0.05)

    PMID 17030114 · one of two readings recorded this

  • serum undercarboxylated osteocalcin (microg/L) and serum phylloquinone over 16 weeks in women given high-calcium skim milk with added phylloquinone 80 microg/d

    decreases, undercarboxylated osteocalcin fell from 9.68 to 4.46 microg/L within the vitamin K-supplemented group

    Not recorded as a finding: the result compares a group with itself, not with a control

    In vitamin K-supplemented women, mean serum phylloquinone concentrations increased from 0.27 to 0.76 microg/L (P < 0.05) and undercarboxylated osteocalcin concentrations decreased from 9.68 to 4.46 microg/L (P < 0.05) over 16 wk.

    PMID 17030114 · one of two readings recorded this

  • total osteocalcin and type I N-terminal procollagen peptide

    decreases

    cross-linked C-telopeptide of type I collagen >30%, total osteocalcin and type I N-terminal procollagen peptide >15%

    PMID 17030114 · one of two readings recorded this

  • undercarboxylated osteocalcin

    decreases, p = 0.05

    undercarboxylated osteocalcin concentrations decreased from 9.68 to 4.46 microg/L (P < 0.05)

    PMID 17030114 · one of two readings recorded this

  • bone mineral at mid-distal radius

    no effect

    Significant bone mineral loss was seen only at the mid-distal radius but with no significant difference between groups

    PMID 17243866 · one of two readings recorded this

  • bone mineral at mid-distal radius

    decreases

    Significant bone mineral loss was seen only at the mid-distal radius but with no significant difference between groups

    PMID 17243866 · one of two readings recorded this

  • bone mineral content and density at the ultradistal radius, DXA

    increases, modest significant increase in BMC at the ultradistal radius, not at other hip or radius sites

    Not recorded as a finding: the intervention held more than the compound

    Combined vitamin K with vitamin D plus calcium was associated with a modest but significant increase in BMC at the ultradistal radius but not at other sites in the hip or radius.

    PMID 17243866 · one of two readings recorded this

  • bone mineral content at other hip and radius sites

    no effect

    Combined vitamin K with vitamin D plus calcium was associated with a modest but significant increase in BMC at the ultradistal radius but not at other sites in the hip or radius

    PMID 17243866 · one of two readings recorded this

  • bone mineral content at ultradistal radius

    increases

    Combined vitamin K with vitamin D plus calcium was associated with a modest but significant increase in BMC at the ultradistal radius but not at other sites in the hip or radius

    PMID 17243866 · one of two readings recorded this

  • bone mineral density at ultradistal radius

    increases

    women who took combined vitamin K and vitamin D plus calcium showed a significant and sustained increase in both BMD and BMC at the site of the ultradistal radius

    PMID 17243866 · one of two readings recorded this

  • parathyroid hormone (PTH)

    decreases, p = 0.049

    Over 2 years, serum vitamin K(1) increased by 157% (p < 0.001), the percentage of undercarboxylated osteocalcin (%GluOC) decreased by 51% (p < 0.001), serum 25-hydroxyvitamin D [25(OH)D] increased by 17% (p < 0.001), and PTH decreased by 11% (p = 0.049)

    PMID 17243866 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%GluOC)

    decreases, p = 0.001

    Over 2 years, serum vitamin K(1) increased by 157% (p < 0.001), the percentage of undercarboxylated osteocalcin (%GluOC) decreased by 51% (p < 0.001), serum 25-hydroxyvitamin D [25(OH)D] increased by 17% (p < 0.001), and PTH decreased by 11% (p = 0.049)

    PMID 17243866 · one of two readings recorded this

  • serum 25-hydroxyvitamin D

    increases, p = 0.001

    Over 2 years, serum vitamin K(1) increased by 157% (p < 0.001), the percentage of undercarboxylated osteocalcin (%GluOC) decreased by 51% (p < 0.001), serum 25-hydroxyvitamin D [25(OH)D] increased by 17% (p < 0.001), and PTH decreased by 11% (p = 0.049)

    PMID 17243866 · one of two readings recorded this

  • serum vitamin K1

    increases, p = 0.001

    Over 2 years, serum vitamin K(1) increased by 157% (p < 0.001), the percentage of undercarboxylated osteocalcin (%GluOC) decreased by 51% (p < 0.001), serum 25-hydroxyvitamin D [25(OH)D] increased by 17% (p < 0.001), and PTH decreased by 11% (p = 0.049)

    PMID 17243866 · one of two readings recorded this

  • serum bone-specific alkaline phosphatase and urinary bone resorption markers (NTx, pyridinoline, deoxypyridinoline)

    no effect, unaffected by phylloquinone supplementation

    Not recorded as a finding: no outcome node for bone-specific ALP or urinary resorption markers; the alkaline-phosphatase node is total serum ALP

    Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation.

    PMID 17298708 · one of two readings recorded this

  • serum bone-specific alkaline phosphatase, assay not stated

    no effect

    Not recorded as a finding: listed alkaline-phosphatase node is total serum ALP by para-nitrophenyl-phosphate assay; paper measured the bone-specific isoform

    Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation.

    PMID 17298708 · one of two readings recorded this

  • serum bone-specific alkaline phosphatase

    no effect

    Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation

    PMID 17298708 · one of two readings recorded this

  • serum gamma-carboxylated osteocalcin

    increases, p = 0.001

    the concentration of serum gamma-carboxylated and under-gamma-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P < 0.001)

    PMID 17298708 · one of two readings recorded this

  • serum phylloquinone concentration, assay not stated

    increases

    Not recorded as a finding: no outcome node for circulating phylloquinone

    Mean serum phylloquinone concentration was significantly (P < 0.001) higher with daily supplementation with 500 microg phylloquinone/d compared with that during either of the placebo or 200 microg phylloquinone/d supplementation periods, which did not differ (P = 0.15).

    PMID 17298708 · one of two readings recorded this

  • serum phylloquinone concentration

    no effect, p = 0.15

    Mean serum phylloquinone concentration was significantly (P < 0.001) higher with daily supplementation with 500 microg phylloquinone/d compared with that during either of the placebo or 200 microg phylloquinone/d supplementation periods, which did not differ (P = 0.15)

    PMID 17298708 · one of two readings recorded this

  • serum phylloquinone concentration

    increases, p = 0.001

    Mean serum phylloquinone concentration was significantly (P < 0.001) higher with daily supplementation with 500 microg phylloquinone/d compared with that during either of the placebo or 200 microg phylloquinone/d supplementation periods, which did not differ (P = 0.15)

    PMID 17298708 · one of two readings recorded this

  • serum total osteocalcin

    increases, increased with 500 but not 200 microg/d vs placebo

    Not recorded as a finding: no outcome node for total osteocalcin

    Serum total osteocalcin was significantly (P < 0.001) increased in response to daily supplementation with 500 (but not 200) microg phylloquinone compared with placebo.

    PMID 17298708 · one of two readings recorded this

  • serum total osteocalcin

    no effect

    Serum total osteocalcin was significantly (P < 0.001) increased in response to daily supplementation with 500 (but not 200) microg phylloquinone compared with placebo

    PMID 17298708 · one of two readings recorded this

  • serum total osteocalcin

    increases, p = 0.001

    Serum total osteocalcin was significantly (P < 0.001) increased in response to daily supplementation with 500 (but not 200) microg phylloquinone compared with placebo

    PMID 17298708 · one of two readings recorded this

  • serum under-gamma-carboxylated osteocalcin

    decreases, p = 0.001

    the concentration of serum gamma-carboxylated and under-gamma-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P < 0.001)

    PMID 17298708 · one of two readings recorded this

  • urinary deoxypyridinoline

    no effect

    Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation

    PMID 17298708 · one of two readings recorded this

  • urinary gamma-carboxyglutamate

    no effect

    Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation

    PMID 17298708 · one of two readings recorded this

  • urinary N-telopeptide cross-links of collagen

    no effect

    Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation

    PMID 17298708 · one of two readings recorded this

  • urinary pyridinoline

    no effect

    Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary gamma-carboxyglutamate were unaffected by phylloquinone supplementation

    PMID 17298708 · one of two readings recorded this

  • maximal INR stability

    increases

    The relative risk (RR) of a maximal stability in the vitamin K group compared to the placebo group was 1.8 (95%, CI 1.1-2.7)

    PMID 17666020 · one of two readings recorded this

  • percentage of time the INR was within the therapeutic range (primary outcome)

    adjusted difference 3.6%; 95% CI -0.8% to 8.0%

    Not recorded as a finding: the paper never states the instrument the node requires

    The time in the therapeutic range was 85.5% in the placebo group and 89.5% in the vitamin K group (adjusted difference 3.6%; 95% CI -0.8% to 8.0%).

    PMID 17666020 · both readings recorded this

  • time above the therapeutic INR range

    no effect

    the time above the therapeutic range was 11.4% in the placebo group and 8.5% in the vitamin K group (adjusted difference -2.9%; 95% CI -6.9% to 1.1%)

    PMID 17666020 · one of two readings recorded this

  • time below the therapeutic INR range

    no effect

    The time below the therapeutic range was 3.1% in the placebo group and 2.1% in the vitamin K group (adjusted difference -0.7%; 95% CI -2.5% to 1.1%)

    PMID 17666020 · one of two readings recorded this

  • time in the therapeutic INR range

    no effect

    The time in the therapeutic range was 85.5% in the placebo group and 89.5% in the vitamin K group (adjusted difference 3.6%; 95% CI -0.8% to 8.0%)

    PMID 17666020 · one of two readings recorded this

  • 3-year change in femoral neck, spine (L2-L4) and total-body BMD, and percent undercarboxylated osteocalcin, with 500 ug/day phylloquinone in a multivitamin versus multivitamin without phylloquinone

    no effect, no differences in BMD change at any site measured between the two groups

    Not recorded as a finding: the supporting sentence never names the compound

    There were no differences in changes in BMD measurements at any of the anatomical sites measured between the two groups.

    PMID 18252784 · one of two readings recorded this

  • change in BMD at femoral neck, spine and total body

    no effect, n = 401

    There were no differences in changes in BMD measurements at any of the anatomical sites measured between the two groups

    PMID 18252784 · one of two readings recorded this

  • femoral neck, spine (L2-L4) and total-body BMD change over 3 years, phylloquinone 500 ug/d in a multivitamin versus multivitamin without phylloquinone

    no effect, no differences in BMD changes at any site between the two groups

    Not recorded as a finding: the supporting sentence never names the compound

    There were no differences in changes in BMD measurements at any of the anatomical sites measured between the two groups.

    PMID 18252784 · one of two readings recorded this

  • other biochemical measures (bone turnover, vitamin D status)

    no effect

    No other biochemical measures differed between the two groups

    PMID 18252784 · one of two readings recorded this

  • percent undercarboxylated osteocalcin

    decreases

    The group that received the phylloquinone supplement had significantly higher phylloquinone and significantly lower percent undercarboxylated osteocalcin concentrations compared with the group that did not receive phylloquinone

    PMID 18252784 · one of two readings recorded this

  • plasma phylloquinone

    increases

    The group that received the phylloquinone supplement had significantly higher phylloquinone and significantly lower percent undercarboxylated osteocalcin concentrations compared with the group that did not receive phylloquinone

    PMID 18252784 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%Glu-OC) and serum vitamin K1 in cystic fibrosis children given 1 mg/day or 5 mg/day vitamin K1 for one month

    decreases, overall %Glu-OC fell from a median of 46.8 to 29.1% (pre/post, both doses pooled)

    Not recorded as a finding: the result compares a group with itself, not with a control

    Supplementation also significantly reduced the overall %Glu-OC from a median of 46.8 to 29.1% (p<0.0003).

    PMID 18511355 · one of two readings recorded this

  • serum vitamin K1 below optimal at baseline

    increases

    Of the 50% of subjects who were below the optimal serum vitamin K1 at baseline, all rose into the normal range with supplementation

    PMID 18511355 · one of two readings recorded this

  • undercarboxylated osteocalcin (%Glu-OC), overall

    decreases, p = 0.0003

    Supplementation also significantly reduced the overall %Glu-OC from a median of 46.8 to 29.1% (p<0.0003)

    PMID 18511355 · one of two readings recorded this

  • participants with insufficient baseline phylloquinone

    n = 222

    222 participants had insufficient phylloquinone concentrations (≤1 nM) at baseline (114 in the treatment arm, 108 in the placebo arm), of whom 125 achieved a concentration of >1 nM by the end of the study

    PMID 18625626 · one of two readings recorded this

  • per-joint prevalence of radiographic hand osteoarthritis, joint space narrowing grade 2 or more and osteophytes, OARSI atlas on hand radiographs, logistic regression with GEE

    no effect, joint space narrowing OR 1.04, 95% CI 0.68 to 1.57, p = 0.9, p = 0.9

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    There was no effect of randomisation to vitamin K supplementation on prevalence of radiographic hand osteoarthritis (OR 1.03, 95% CI 0.80 to 1.34, p = 0.8), joint space narrowing (OR 1.04, 95% CI 0.68 to 1.57, p = 0.9) or osteophytes (OR 0.95, 95% CI 0.64 to 1.40, p = 0.8).

    PMID 18625626 · one of two readings recorded this

  • per-joint prevalence of radiographic hand osteoarthritis (Kellgren-Lawrence grade 2 or more), joint space narrowing (OARSI grade 2 or more) and osteophytes on hand radiographs at 3 years

    no effect, hand OA OR 1.03 (95% CI 0.80 to 1.34); joint space narrowing OR 1.04 (0.68 to 1.57); osteophytes OR 0.95 (0.64 to 1.40)

    Not recorded as a finding: this platform holds no node for the endpoint

    There was no effect of randomisation to vitamin K supplementation on prevalence of radiographic hand osteoarthritis (OR 1.03, 95% CI 0.80 to 1.34, p = 0.8), joint space narrowing (OR 1.04, 95% CI 0.68 to 1.57, p = 0.9) or osteophytes (OR 0.95, 95% CI 0.64 to 1.40, p = 0.8).

    PMID 18625626 · one of two readings recorded this

  • prevalence of joint space narrowing

    no effect, p = 0.9

    joint space narrowing (OR 1.04, 95% CI 0.68 to 1.57, p = 0.9)

    PMID 18625626 · one of two readings recorded this

  • prevalence of joint space narrowing

    decreases, p = 0.02

    trends towards 47% lower prevalence of joint space narrowing (95% CI 0.32 to 0.89, p = 0.02)

    PMID 18625626 · one of two readings recorded this

  • prevalence of osteophytes

    no effect, p = 0.8

    osteophytes (OR 0.95, 95% CI 0.64 to 1.40, p = 0.8)

    PMID 18625626 · one of two readings recorded this

  • prevalence of osteophytes

    no effect, p = 0.5

    osteophytes (OR = 0.88, 95% CI 0.56 to 1.40, p = 0.5)

    PMID 18625626 · one of two readings recorded this

  • prevalence of radiographic hand osteoarthritis

    no effect, p = 0.8

    radiographic hand osteoarthritis (OR 1.03, 95% CI 0.80 to 1.34, p = 0.8)

    PMID 18625626 · one of two readings recorded this

  • prevalence of radiographic hand osteoarthritis

    no effect, p = 0.1

    radiographic osteoarthritis (OR = 0.78, 95% CI 0.56 to 1.07, p = 0.1)

    PMID 18625626 · one of two readings recorded this

  • prevalence of radiographic osteoarthritis in at least 1 first carpometacarpal joint

    Overall, 52.9% had >2 hand joints, 34.9% had >2 distal interphalangeal joints, and 37.3% had ≥1 first carpometacarpal joint involved with radiographic osteoarthritis, respectively

    PMID 18625626 · one of two readings recorded this

  • prevalence of radiographic osteoarthritis in more than 2 distal interphalangeal joints

    Overall, 52.9% had >2 hand joints, 34.9% had >2 distal interphalangeal joints, and 37.3% had ≥1 first carpometacarpal joint involved with radiographic osteoarthritis, respectively

    PMID 18625626 · one of two readings recorded this

  • prevalence of radiographic osteoarthritis in more than 2 hand joints

    Overall, 52.9% had >2 hand joints, 34.9% had >2 distal interphalangeal joints, and 37.3% had ≥1 first carpometacarpal joint involved with radiographic osteoarthritis, respectively

    PMID 18625626 · one of two readings recorded this

  • 3-y change in osteoprotegerin between treatment groups

    no effect

    However, the mean difference in change in osteoprotegerin between the treatment groups was not statistically significant

    PMID 18689371 · one of two readings recorded this

  • adherence to supplement (percentage of tablets consumed over 3 y)

    was 89.1% for the group supplemented with the multivitamin with phylloquinone and 88.5% for the group who received the multivitamin without phylloquinone

    PMID 18689371 · one of two readings recorded this

  • age-related bone loss (BMD)

    no effect

    Because there was no effect of vitamin K supplementation on circulating cytokine concentrations or on age-related bone loss

    PMID 18689371 · one of two readings recorded this

  • antiinflammatory medication use

    decreases, p = 0.01

    Overall, use of statin medication significantly increased to 36%, and antiinflammatory medication use (steroidal or non-steroidal) significantly decreased to 13.4% by year 3 (both P < 0.01)

    PMID 18689371 · one of two readings recorded this

  • association between change in CRP and change in total body BMD

    increases, p = 0.01

    with the exception of a significant positive association between change in CRP and change in total body BMD (P = 0.01)

    PMID 18689371 · one of two readings recorded this

  • association of osteoprotegerin with total osteocalcin

    no effect, p = 0.05

    Serum osteoprotegerin was not associated with total osteocalcin in any model (all P > 0.05)

    PMID 18689371 · one of two readings recorded this

  • association of plasma phylloquinone with CRP

    decreases, p = 0.04

    plasma phylloquinone was significantly and inversely associated with CRP and IL-6 in age- and sex-adjusted analyses (P = 0.04 and 0.02, respectively, 2-sided)

    PMID 18689371 · one of two readings recorded this

  • association of plasma phylloquinone with IL-6

    decreases, p = 0.02

    plasma phylloquinone was significantly and inversely associated with CRP and IL-6 in age- and sex-adjusted analyses (P = 0.04 and 0.02, respectively, 2-sided)

    PMID 18689371 · one of two readings recorded this

  • association of plasma phylloquinone with osteoprotegerin

    increases, p = 0.02

    plasma phylloquinone was positively associated with circulating osteoprotegerin in all models (P = 0.02)

    PMID 18689371 · one of two readings recorded this

  • association of total osteocalcin with CRP

    decreases, p = 0.01

    an increase of 10 ng/mL in circulating osteocalcin was associated with a 0.73-fold decrease in CRP and a 0.84-fold decrease in IL-6 in fully adjusted models (all P < 0.01)

    PMID 18689371 · one of two readings recorded this

  • association of total osteocalcin with IL-6

    decreases, p = 0.01

    an increase of 10 ng/mL in circulating osteocalcin was associated with a 0.73-fold decrease in CRP and a 0.84-fold decrease in IL-6 in fully adjusted models (all P < 0.01)

    PMID 18689371 · one of two readings recorded this

  • association of %ucOC with IL-6

    decreases, p = 0.01

    The %ucOC was inversely associated with IL-6 and osteoprotegerin in all models (P < 0.01)

    PMID 18689371 · one of two readings recorded this

  • association of %ucOC with osteoprotegerin

    decreases, p = 0.01

    The %ucOC was inversely associated with IL-6 and osteoprotegerin in all models (P < 0.01)

    PMID 18689371 · one of two readings recorded this

  • baseline dietary phylloquinone intake

    Reported intakes of phylloquinone were higher than current recommendations at baseline in both groups (183 ± 108 μg/d in the vitamin K treatment group and 172 ± 111 μg/d in the non–vitamin K treatment group)

    PMID 18689371 · one of two readings recorded this

  • circulating cytokine concentrations

    no effect

    Because there was no effect of vitamin K supplementation on circulating cytokine concentrations or on age-related bone loss

    PMID 18689371 · one of two readings recorded this

  • CRP concentration, end of study versus baseline

    no effect

    The mean concentrations of CRP and IL-6 at the end of the 3-y study did not significantly differ from baseline concentrations in either group or when data from the 2 groups were combined

    PMID 18689371 · one of two readings recorded this

  • IL-6 concentration, end of study versus baseline

    no effect

    The mean concentrations of CRP and IL-6 at the end of the 3-y study did not significantly differ from baseline concentrations in either group or when data from the 2 groups were combined

    PMID 18689371 · one of two readings recorded this

  • lumbar spine BMD change, groups combined

    increases, p = 0.05

    Increases in BMD at the lumbar spine (x̄ ± SD: 0.02 ± 0.05 g/cm2) and decreases in total body BMD (–0.01 ± 0.03 g/cm2) were observed between baseline and year 3 in both groups (P < 0.05)

    PMID 18689371 · one of two readings recorded this

  • osteoprotegerin concentration, end of study versus baseline

    increases, p = 0.01

    A statistically significant increase overall was observed in the mean concentration of osteoprotegerin in both groups (P < 0.01, repeated-measures ANOVA)

    PMID 18689371 · one of two readings recorded this

  • plasma phylloquinone

    increases, p = 0.01

    Plasma phylloquinone increased [P < 0.01, repeated-measures analysis of variance (ANOVA)] and %ucOC decreased (P < 0.01, repeated measures ANOVA) after 3 y in the group that received phylloquinone supplementation

    PMID 18689371 · one of two readings recorded this

  • serum percentage undercarboxylated osteocalcin (%ucOC)

    decreases, p = 0.01

    Plasma phylloquinone increased [P < 0.01, repeated-measures analysis of variance (ANOVA)] and %ucOC decreased (P < 0.01, repeated measures ANOVA) after 3 y in the group that received phylloquinone supplementation

    PMID 18689371 · one of two readings recorded this

  • statin medication use

    increases, p = 0.01

    Overall, use of statin medication significantly increased to 36%, and antiinflammatory medication use (steroidal or non-steroidal) significantly decreased to 13.4% by year 3 (both P < 0.01)

    PMID 18689371 · one of two readings recorded this

  • total body BMD change, groups combined

    decreases, p = 0.05

    Increases in BMD at the lumbar spine (x̄ ± SD: 0.02 ± 0.05 g/cm2) and decreases in total body BMD (–0.01 ± 0.03 g/cm2) were observed between baseline and year 3 in both groups (P < 0.05)

    PMID 18689371 · one of two readings recorded this

  • HOMA-IR

    decreases

    HOMA-IR and plasma insulin concentrations were statistically significantly lower at the 36-month visit among men in the supplement group versus men in the control group

    PMID 18697901 · one of two readings recorded this

  • HOMA-IR

    no effect

    There was no significant difference among men in HOMA-IR and plasma insulin at the 6-month visit

    PMID 18697901 · one of two readings recorded this

  • HOMA-IR

    decreases, p = 0.03

    differences among men in HOMA-IR were still statistically different (P = 0.03), whereas there was attenuation in differences in the plasma insulin (P = 0.07)

    PMID 18697901 · one of two readings recorded this

  • 36-month change in fasting plasma insulin

    decreases, p = 0.03

    insulin, −0.46 [−1.56 to 0.65] vs. 1.47 [0.22 to 2.71], P = 0.03

    PMID 18697901 · one of two readings recorded this

  • 36-month change in HOMA-IR

    decreases, p = 0.01

    HOMA-IR, −0.11 [95% CI −0.40 to 0.19] vs. 0.47 [0.15 to 0.80], P = 0.01

    PMID 18697901 · one of two readings recorded this

  • 36-month change in percent undercarboxylated osteocalcin, treated versus control

    decreases, p = 0.001

    36-month changes in plasma phylloquinone and percent undercarboxylated osteocalcin were significantly different from those of the control group for both men and women (P < 0.001)

    PMID 18697901 · one of two readings recorded this

  • 36-month change in percent undercarboxylated osteocalcin

    0.4 ± 17.7% for men and 2.3% ± 21.2% for women in the control group

    PMID 18697901 · one of two readings recorded this

  • 36-month change in percent undercarboxylated osteocalcin

    0.4 ± 17.7% for men and 2.3% ± 21.2% for women in the control group

    PMID 18697901 · one of two readings recorded this

  • 36-month change in percent undercarboxylated osteocalcin

    decreases

    were −19.0 ± 23.4% for men and −19.3 ± 20.5% for women in the treated group

    PMID 18697901 · one of two readings recorded this

  • 36-month change in percent undercarboxylated osteocalcin

    decreases

    were −19.0 ± 23.4% for men and −19.3 ± 20.5% for women in the treated group

    PMID 18697901 · one of two readings recorded this

  • 36-month change in plasma phylloquinone, treated versus control

    increases, p = 0.001

    36-month changes in plasma phylloquinone and percent undercarboxylated osteocalcin were significantly different from those of the control group for both men and women (P < 0.001)

    PMID 18697901 · one of two readings recorded this

  • 36-month change in plasma phylloquinone

    whereas the changes in the men and women in the control group were −0.2 ± 1.9 and 0.1 ± 1.3 nmol/l, respectively

    PMID 18697901 · one of two readings recorded this

  • 36-month change in plasma phylloquinone

    whereas the changes in the men and women in the control group were −0.2 ± 1.9 and 0.1 ± 1.3 nmol/l, respectively

    PMID 18697901 · one of two readings recorded this

  • 36-month change in plasma phylloquinone

    increases

    The mean ± SD 36-month changes in plasma phylloquinone concentrations for men and women receiving the vitamin K supplement were 1.4 ± 2.5 and 2.3 ± 2.8 nmol/l, respectively

    PMID 18697901 · one of two readings recorded this

  • 36-month change in plasma phylloquinone

    increases

    The mean ± SD 36-month changes in plasma phylloquinone concentrations for men and women receiving the vitamin K supplement were 1.4 ± 2.5 and 2.3 ± 2.8 nmol/l, respectively

    PMID 18697901 · one of two readings recorded this

  • association of plasma phylloquinone with BMI (triglyceride-adjusted partial correlation)

    decreases, p = 0.02

    we found that plasma phylloquinone concentrations were inversely associated with BMI in women, but not in men, after adjustment for plasma triglycerides (Pearson's partial r = −0.15, P = 0.02)

    PMID 18697901 · one of two readings recorded this

  • change in body fat

    increases, p = 0.001

    In men, mean body weight decreased by 0.5 kg (P = 0.02) and body fat increased by 0.5% (P = 0.001), respectively

    PMID 18697901 · one of two readings recorded this

  • change in body weight

    decreases, p = 0.02

    In men, mean body weight decreased by 0.5 kg (P = 0.02) and body fat increased by 0.5% (P = 0.001), respectively

    PMID 18697901 · one of two readings recorded this

  • change in fasting plasma glucose

    no effect

    There were no statistically significant differences in changes in HOMA-IR, fasting plasma insulin, and glucose between women in the vitamin K–treated groups and control group

    PMID 18697901 · one of two readings recorded this

  • change in fasting plasma insulin

    no effect

    There were no statistically significant differences in changes in HOMA-IR, fasting plasma insulin, and glucose between women in the vitamin K–treated groups and control group

    PMID 18697901 · one of two readings recorded this

  • change in HOMA-IR

    no effect

    There were no statistically significant differences in changes in HOMA-IR, fasting plasma insulin, and glucose between women in the vitamin K–treated groups and control group

    PMID 18697901 · one of two readings recorded this

  • change in percent body fat

    increases, p = 0.002

    Among women in our study, there was a significant increase in mean percent body fat of 0.6% over the 36 months (P = 0.002)

    PMID 18697901 · one of two readings recorded this

  • fasting plasma glucose

    no effect

    Fasting plasma glucose concentrations among men did not differ between two study groups at any time point

    PMID 18697901 · one of two readings recorded this

  • fasting plasma insulin

    decreases

    HOMA-IR and plasma insulin concentrations were statistically significantly lower at the 36-month visit among men in the supplement group versus men in the control group

    PMID 18697901 · one of two readings recorded this

  • fasting plasma insulin

    no effect

    There was no significant difference among men in HOMA-IR and plasma insulin at the 6-month visit

    PMID 18697901 · one of two readings recorded this

  • fasting plasma insulin

    unclear, p = 0.07

    differences among men in HOMA-IR were still statistically different (P = 0.03), whereas there was attenuation in differences in the plasma insulin (P = 0.07)

    PMID 18697901 · one of two readings recorded this

  • HOMA-IR at 36 months (primary), fasting plasma insulin and glucose (secondary), analysed separately in men and women after a significant sex-by-treatment interaction

    decreases, HOMA-IR and insulin lower among men on supplement versus control at 36 months

    Not recorded as a finding: every result is a subgroup, with no whole-population estimate

    HOMA-IR and plasma insulin concentrations were statistically significantly lower at the 36-month visit among men in the supplement group versus men in the control group after adjustment for baseline HOMA-IR, BMI, and weight change (Table 2).

    PMID 18697901 · one of two readings recorded this

  • HOMA-IR at 36 months (primary), fasting plasma insulin and glucose (secondary), phylloquinone 500 ug/day versus multivitamin without phylloquinone

    decreases, HOMA-IR and plasma insulin lower at 36 months among men in the supplement group; no significant differences among women

    Not recorded as a finding: every result is a subgroup, with no whole-population estimate

    HOMA-IR and plasma insulin concentrations were statistically significantly lower at the 36-month visit among men in the supplement group versus men in the control group after adjustment for baseline HOMA-IR, BMI, and weight change (Table 2).

    PMID 18697901 · one of two readings recorded this

  • health-related quality of life

    no effect

    There was no difference in health-related quality of life between groups

    PMID 18922041 · one of two readings recorded this

  • baseline Gail breast cancer risk score

    no effect

    we calculated the Gail breast cancer risk score from baseline data and found that there was no difference between the vitamin K and the placebo groups (1.70% versus 1.71% risk of having invasive breast cancer in the next 5 y)

    PMID 18922041 · one of two readings recorded this

  • cancer incidence

    decreases, p = 0.02

    Cancer incidence was lower in the vitamin K group than in the placebo group (three versus 12, p = 0.02; HR = 0.25, 95% CI 0.07 to 0.89)

    PMID 18922041 · one of two readings recorded this

  • clinical fractures (time to first)

    no effect, p = 0.08

    hazard ratio [HR] = 0.41, 95% CI 0.15 to 1.18, p = 0.08 at 2 y

    PMID 18922041 · one of two readings recorded this

  • clinical fractures (time to first)

    decreases, p = 0.04

    HR = 0.45, 95% CI 0.20 to 0.98, p = 0.04 at 4 y

    PMID 18922041 · one of two readings recorded this

  • femoral neck BMD difference between groups

    unclear

    With the exception of a 1.7% difference in BMD at the femoral neck between the two groups at 36 mo

    PMID 18922041 · one of two readings recorded this

  • fragility fractures

    no effect, p = 0.11

    six fractures sustained by four women on vitamin K and 11 fractures sustained by ten women on placebo, p = 0.11

    PMID 18922041 · one of two readings recorded this

  • height change

    no effect

    There was no difference in mean changes in height between groups

    PMID 18922041 · one of two readings recorded this

  • lumbar spine BMD percentage change over 2 y by DXA, primary outcome

    -1.28% vs -1.22%, p = 0.84, difference -0.06% (95% CI -0.67% to 0.54%), p = 0.84

    Not recorded as a finding: Sentence reports both arms decreased with a p value and no direction word for the between-arm contrast (direction_stated_but_not_significant)

    In the vitamin K and placebo groups, respectively, BMD decreased by −1.28% and −1.22% (p = 0.84) (difference of −0.06%; 95% confidence interval [CI], −0.67% to 0.54%) at the lumbar spine and −0.69% and −0.88% (p = 0.51) (difference of 0.19%; 95% CI −0.37% to 0.75%) at the total hip over 2 y.

    PMID 18922041 · one of two readings recorded this

  • lumbar spine BMD percentage change

    no effect, p = 0.84

    BMD decreased by −1.28% and −1.22% (p = 0.84) (difference of −0.06%; 95% confidence interval [CI], −0.67% to 0.54%) at the lumbar spine

    PMID 18922041 · one of two readings recorded this

  • new morphometric vertebral fractures on VFA

    no effect, p = 0.56

    A total of 47 women had new morphometric vertebral fractures on VFA (most were Grade 1 fractures): 25 in the vitamin K group and 22 in the placebo group (p = 0.56)

    PMID 18922041 · one of two readings recorded this

  • percentage of undercarboxylated osteocalcin (%ucOC) change

    decreases, p = 0.0001

    Vitamin K1 supplementation decreased ucOC and percentage of ucOC (−52.8% versus −3.5%, p < 0.0001, and −21.4% versus −2.0%, p < 0.0001 at 2 y, respectively)

    PMID 18922041 · one of two readings recorded this

  • serum CTX

    no effect, p = 0.07

    serum CTX levels were similar between groups (0.58 ng/ml versus 0.54 ng/ml, p = 0.07)

    PMID 18922041 · one of two readings recorded this

  • serum total osteocalcin

    decreases, p = 0.0001

    serum total OC levels decreased (21 ng/ml versus 24 ng/ml, p < 0.0001) in women supplemented with vitamin K compared to placebo

    PMID 18922041 · one of two readings recorded this

  • serum vitamin K1 concentration by HPLC with fluorometric detection, 2 y

    increases, 22.6 nmol/l versus 2.0 nmol/l at 2 y

    Not recorded as a finding: No node for circulating phylloquinone after supplementation

    Daily 5 mg of vitamin K1 supplementation increased serum vitamin K1 levels (22.6 nmol/l versus 2.0 nmol/l, p < 0.0001 at 2 y), but did not increase circulating vitamin K2 (menaquinones 4 and 7) levels.

    PMID 18922041 · one of two readings recorded this

  • serum vitamin K1

    increases, p = 0.0001

    Daily 5 mg of vitamin K1 supplementation increased serum vitamin K1 levels (22.6 nmol/l versus 2.0 nmol/l, p < 0.0001 at 2 y)

    PMID 18922041 · one of two readings recorded this

  • serum vitamin K2 (menaquinones 4 and 7)

    no effect

    but did not increase circulating vitamin K2 (menaquinones 4 and 7) levels

    PMID 18922041 · one of two readings recorded this

  • total hip BMD percentage change

    no effect, p = 0.51

    −0.69% and −0.88% (p = 0.51) (difference of 0.19%; 95% CI −0.37% to 0.75%) at the total hip over 2 y

    PMID 18922041 · one of two readings recorded this

  • undercarboxylated osteocalcin (ucOC) change

    decreases, p = 0.0001

    Vitamin K1 supplementation decreased ucOC and percentage of ucOC (−52.8% versus −3.5%, p < 0.0001, and −21.4% versus −2.0%, p < 0.0001 at 2 y, respectively)

    PMID 18922041 · one of two readings recorded this

  • greater trochanter BMD

    unclear, p = 0.011

    When BMD was measured across time, C had a significant increase (P = .011) in greater trochanter BMD compared to E

    PMID 19083462 · one of two readings recorded this

  • serum osteocalcin

    no effect

    There was no significant difference between E and C in serum osteocalcin concentrations over time

    PMID 19083462 · one of two readings recorded this

  • shaft BMD

    no effect, p = 0.067

    The E group had a nonsignificant increase (P = .067) in shaft BMD compared to the C group

    PMID 19083462 · one of two readings recorded this

  • urinary N-telopeptide

    increases, p = 0.008

    Urinary N-telopeptide levels increased significantly over time in E compared to C (P = .008)

    PMID 19083462 · one of two readings recorded this

  • coronary artery calcium (CAC) progression, change in Agatston score over 3 years, phylloquinone 500 ug/d in a multivitamin versus multivitamin alone

    no effect, ITT mean Agatston changes 27 +/- 6 versus 37 +/- 7, no difference

    Not recorded as a finding: this platform holds no node for the endpoint

    In an intention-to-treat analysis, there was no difference in CAC progression between the phylloquinone group and the control group; the mean (+/-SEM) changes in Agatston scores were 27 +/- 6 and 37 +/- 7, respectively.

    PMID 19386744 · one of two readings recorded this

  • coronary artery calcium progression, change in Agatston score over 3 years

    no effect, mean changes in Agatston scores 27 and 37, phylloquinone versus control, intention-to-treat

    Not recorded as a finding: this platform holds no node for the endpoint

    In an intention-to-treat analysis, there was no difference in CAC progression between the phylloquinone group and the control group; the mean (+/-SEM) changes in Agatston scores were 27 +/- 6 and 37 +/- 7, respectively.

    PMID 19386744 · one of two readings recorded this

  • coronary artery calcium progression (change in Agatston score)

    no effect

    In an intention-to-treat analysis, there was no difference in CAC progression between the phylloquinone group and the control group; the mean (+/-SEM) changes in Agatston scores were 27 +/- 6 and 37 +/- 7, respectively

    PMID 19386744 · one of two readings recorded this

  • coronary artery calcium progression

    decreases, p = 0.03, n = 367

    In a subgroup analysis of participants who were > or =85% adherent to supplementation (n = 367), there was less CAC progression in the phylloquinone group than in the control group (P = 0.03)

    PMID 19386744 · one of two readings recorded this

  • coronary artery calcium progression

    decreases, p = 0.04

    those who received phylloquinone supplements had 6% less progression than did those who received the multivitamin alone (P = 0.04)

    PMID 19386744 · one of two readings recorded this

  • serum matrix Gla protein (MGP) change as explanation for CAC progression decrease

    no effect

    Phylloquinone-associated decreases in CAC progression were independent of changes in serum MGP

    PMID 19386744 · one of two readings recorded this

  • HOMA-IR at 12 months

    no effect

    at 12 mo, HOMA-IR was 2.13 ± 0.38 and 1.47 ± 0.22 in the experimental and control groups, respectively

    PMID 20881072 · one of two readings recorded this

  • HOMA-IR at 6 months

    no effect

    at 6 mo, HOMA-IR was 2.24 ± 0.54 and 1.52 ± 0.23 in the experimental and control groups, respectively

    PMID 20881072 · one of two readings recorded this

  • HOMA-IR at baseline

    no effect

    Before administration of the placebo or phylloquinone, total osteocalcin, ucOC, glucose, and insulin concentrations and HOMA-IR (1.24 ± 0.15 for the control group compared with 1.93 ± 0.37 for the experimental group) did not differ

    PMID 20881072 · one of two readings recorded this

  • Serum ucOC concentration at 12 months

    decreases, p = 0.001

    At 12 mo, serum ucOC concentrations were 0.92 ± 0.09 ng/mL and 3.13 ± 0.26 ng/mL (P < 0.001) in experimental and control groups, respectively

    PMID 20881072 · one of two readings recorded this

  • Serum ucOC concentration at 6 months

    decreases, p = 0.001

    At 6 mo, serum ucOC concentrations in the experimental group were 0.96 ± 0.08 ng/mL compared with 2.94 ± 0.27 ng/mL in the control group (P < 0.001)

    PMID 20881072 · one of two readings recorded this

  • Serum ucOC concentration, decrease in magnitude

    decreases

    Despite a decrease of ≈200% in ucOC concentrations, HOMA-IR was similar in the 2 groups at 6 and 12 mo

    PMID 20881072 · one of two readings recorded this

  • serum undercarboxylated osteocalcin (ucOC), 6 and 12 months

    Not recorded as a finding: Direction is carried only by the two concentrations in the sentence, with no direction word naming the compound's effect

    At 6 mo, serum ucOC concentrations in the experimental group were 0.96 ± 0.08 ng/mL compared with 2.94 ± 0.27 ng/mL in the control group (P < 0.001).

    PMID 20881072 · one of two readings recorded this

  • serum undercarboxylated osteocalcin (ucOC) concentration

    Not recorded as a finding: direction carried only by the estimates, no direction word in the sentence

    At 12 mo, serum ucOC concentrations were 0.92 ± 0.09 ng/mL and 3.13 ± 0.26 ng/mL (P < 0.001) in experimental and control groups, respectively.

    PMID 20881072 · one of two readings recorded this

  • Total serum osteocalcin concentration at 6 and 12 months

    no effect

    After treatment, total osteocalcin concentrations were similar at 6 and 12 mo

    PMID 20881072 · one of two readings recorded this

  • Chance of reaching at least 85% of time with INR within the therapeutic range

    increases

    The patients from both the 100 μg group and the 150 μg group had a 2-fold higher chance of reaching at least 85% of time with the International Normalized Ratio within the therapeutic range

    PMID 21193422 · one of two readings recorded this

The whole record — 918 rows